Thyrocare Technologies Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "Press Release on Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2025".
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare Technologies reported strong Q1FY26 (quarter ended June 30, 2025) results with consolidated revenue of INR 193.03 Cr, up 23% year-on-year from INR 156.91 Cr. Normalized EBITDA grew 42% YoY to INR 63.35 Cr, while profit after tax surged 62% YoY to INR 38.06 Cr. Growth was led by the Pathology segment (+25% YoY), with franchise revenue up 20% and partnership revenue up 36%. Total test volume rose 15% YoY to 46.9 million. Margins expanded across the board — normalized EBITDA margin improved to 33% (from 29%) and PAT margin to 20% (from 15%). The company also opened new labs in Bhagalpur, Kashmir, and Roorkee, and now has 9,500+ active franchises.
A broad-based beat on revenue, profitability, and margins signals strong operating momentum in Thyrocare's core diagnostics business, which is likely to be viewed positively by investors. The significant PAT growth of 62% YoY and margin expansion suggest improving scale benefits and cost efficiency, potentially supporting a positive short-term stock reaction.